-
Article
Open AccessSelection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer
Use of gonadotropin-releasing hormone (GnRH) agonists has been widely adopted to provide reversible ovarian function suppression for pre-menopausal breast cancer patients who are also receiving aromatase inhib...
-
Article
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study
Chemotherapy with or without immunotherapy remains the mainstay of treatment for triple-negative breast cancer (TNBC). A subset of TNBCs express the androgen receptor (AR), representing a potential new therape...
-
Article
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
Rash develops in approximately 50% of patients receiving alpelisib for breast cancer, often requiring dose modifications. Here, we describe the clinicopathologic, laboratory, and management characteristics of ...
-
Article
Male breast cancer: a disease distinct from female breast cancer
Male breast cancer (BC) is rare, representing approximately 1% of cancers that occur in men and approximately 1% of all BCs worldwide. Because male BC is rare, not much is known about the disease, and treatmen...
-
Chapter
Emerging Novel Therapeutics in Triple-Negative Breast Cancer
The mortality from breast cancer has steadily decreased due in part to early detection and advances in therapy. The treatment options for breast cancer vary considerably depending on the histological subtype. ...
-
Article
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer
Seviteronel (INO-464) is an oral, selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) and androgen receptor inhibitor with in vitro and in vivo anti-tumor activity. This open-label phase 1 clinical study...
-
Article
First international TNBC conference meeting report
Recently, Georgia State University’s Centennial Hall was the premier location for the 2017 International Conference on Triple Negative Breast Cancer (TNBC): Illuminating Actionable Biology, which was held from...
-
Article
Androgen Receptor-Targeted Therapy for Breast Cancer
Emerging evidence has identified the androgen receptor (AR) pathway as a potential driver for breast cancer (BC) carcinogenesis. The prevalence of AR expression differs across breast cancer subtypes, and its p...
-
Reference Work Entry In depth
Log-Kill Hypothesis
-
Reference Work Entry In depth
Norton-Simon Hypothesis
-
Article
Open AccessDecreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review
Capecitabine is widely used in the management of metastatic breast cancer; however, drug delivery is limited by gastrointestinal and other toxicity. We employed mathematical modeling to rationally design an op...
-
Living Reference Work Entry In depth
Norton-Simon Hypothesis
-
Living Reference Work Entry In depth
Log-Kill Hypothesis
-
Article
Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis
Triple-negative breast cancer (TNBC) disproportionately affects black women. However, black race as a prognostic factor in TNBC has not been well studied. We evaluated the effect of race, among other variables...
-
Chapter
Understanding Triple-Negative Breast Cancer
It is estimated that over 200,000 new cases of invasive breast cancer will be diagnosed in the United States in 2012 and approximately 40,000 women will die from their disease. Triple-negative breast cancer (T...
-
Article
The Androgen Receptor in Breast Cancer: Biology and Treatment Considerations
The androgen receptor (AR) is expressed in 70–90% of invasive breast cancers. Despite the ubiquitous expression of AR in both primary and metastatic breast cancers, the clinical significance of this hormone re...
-
Article
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
Our group applied mathematical modeling to capecitabine dosing and predicted 7 days of treatment followed by 7 days of rest (7–7) would improve efficacy and minimize toxicity. The conventional schedule of cape...
-
Reference Work Entry In depth
Log-Kill Hypothesis
-
Reference Work Entry In depth
Norton-Simon Hypothesis
-
Article
Targeting insulin-like growth factor type 1 receptor in cancer therapy
It is believed that the insulin-like growth factor receptor type 1 (IGF-1R) signaling pathway plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies. Strategies are being de...
